Home / TRANCE/TNFSF11/RANK L / Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Catalog #: 390-TN
39 Citations 8 Reviews Datasheet / COA / SDS
Newer Version Available: 6449-TEC
NEW
A New rh TRANCE is Now Available! The new protein has no tag!

Carrier Free

Catalog # Availability Size / Price Qty
390-TN-010/CF

With Carrier

Catalog # Availability Size / Price Qty
390-TN-010
Graph showing dose-dependent bioactivity of Human TRANCE protein
1 Image
Product Details
Citations (39)
FAQs
Reviews (8)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human TRANCE/RANK L/TNFSF11 Protein Summary

Product Specifications

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050).
Source
Mouse myeloma cell line, NS0-derived human TRANCE/TNFSF11/RANK L protein
MHHHHHHHHHH GGGSGGGSGGGS IEGR Human TRANCE
(Gly64-Asp245)
Accession # AAC51762
N-terminus C-terminus
Accession #
AAC51762
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
23 kDa
SDS-PAGE
35 kDa, reducing conditions

Product Datasheets

You must select a language.

x

390-TN (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

390-TN/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

390-TN

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

390-TN/CF

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Graph showing dose-dependent bioactivity of Human TRANCE protein View Larger

Recombinant human TRANCE / RANK L / TNFSF11 (390-TN) induces osteoclast differentiation of the RAW264.7 mouse monocyte/macrophage cell line. The ED50 for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TRANCE/TNFSF11/RANK L

RANK Ligand (receptor activator of NF-kappa B ligand [RANKL], also called TNF-related activation-induced cytokines (TRANCE), osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]), is a member of the tumor necrosis factor (TNF) family. RANK Ligand was originally identified as an immediate early gene up‑regulated by T cell receptor stimulation. The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids. The extracellular domain contains two potential N‑linked glycosylation sites. Mouse and human RANK Ligand share 85% amino acid identity. RANK Ligand is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes. The multi-functions of RANK Ligand include induction of activation of the c-jun N‑terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis, and lymph node organogenesis. RANK is the cell surface signaling receptor of RANK Ligand. RANK has been shown to undergo receptor clustering during signal transduction. Osteoprotegerin, a soluble member of the TNF receptor family which binds RANK Ligand, is a naturally occurring decoy receptor that counterbalances the effects of RANK Ligand.

References
  1. Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
  2. Anderson, D.M. et al. (1997) Nature 390:175.
  3. Nakagawa, N. et al. (1998) Biochem. Biophys. Res. Commun. 245:382.
  4. Kong, Y-Y. et al. (1999) Nature 397:315.
Long Name
TNF-related Activation-induced Cytokine
Entrez Gene IDs
8600 (Human); 21943 (Mouse); 117516 (Rat); 102137946 (Cynomolgus Monkey)
Alternate Names
CD254 antigen; CD254; ODF; OPGL; OPGLOPTB2; Osteoclast differentiation factor; Osteoprotegerin ligand; RANK L; RANKL; RANKLreceptor activator of nuclear factor kappa B ligand; Receptor activator of nuclear factor kappa-B ligand; sOdf; TNF-related activation-induced cytokine; TNFSF11; TRANCE; TRANCEODFhRANKL2; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand superfamily member 11

Citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

39 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model
    Authors: J Pape, D Bakkalci, RA Hosni, BS Simpson, K Heikinheim, S Fedele, U Cheema
    Journal of tissue engineering, 2022-12-24;13(0):2041731422114.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  2. Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption
    Authors: D Ding, L Wang, J Yan, Y Zhou, G Feng, L Ma, Y Yang, X Pei, Q Jin
    PLoS ONE, 2022-07-28;17(7):e0271485.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway
    Authors: H Guo, D Ding, L Wang, J Yan, L Ma, Q Jin
    PLoS ONE, 2021-12-16;16(12):e0261127.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  4. CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK
    Authors: J Xue, L Xu, H Zhu, M Bai, X Li, Z Zhao, H Zhong, G Cheng, X Li, F Hu, Y Su
    Arthritis Research & Therapy, 2020-09-21;22(1):221.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Environmental arginine controls multinuclear giant cell metabolism and formation
    Authors: JS Brunner, L Vulliard, M Hofmann, M Kieler, A Lercher, A Vogel, M Russier, JB Brüggenthi, M Kerndl, V Saferding, B Niederreit, A Junza, A Frauenstei, C Scholtysek, Y Mikami, K Klavins, G Krönke, A Bergthaler, JJ O'Shea, T Weichhart, F Meissner, JS Smolen, P Cheng, O Yanes, J Menche, PJ Murray, O Sharif, S Blüml, G Schabbauer
    Nat Commun, 2020-01-22;11(1):431.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  6. Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis
    Authors: KA Lee, KW Kim, BM Kim, JY Won, HK Min, DW Lee, HR Kim, SH Lee
    Arthritis Res. Ther., 2019-12-12;21(1):283.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
    Authors: I Zoi, MV Karamouzis, E Xingi, P Sarantis, D Thomaidou, P Lembessis, S Theocharis, AG Papavassil
    Breast Cancer Res., 2019-12-03;21(1):132.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation
    Authors: K Li, S Chen, P Cai, K Chen, L Li, X Yang, J Yi, X Luo, Y Du, H Zheng
    Mol. Cell. Probes, 2019-11-06;0(0):101479.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  9. Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps
    Authors: N Ogasawara, JA Poposki, AI Klingler, BK Tan, KE Hulse, WW Stevens, AT Peters, LC Grammer, KC Welch, SS Smith, DB Conley, JR Raviv, P Soroosh, KI Takano, T Himi, RC Kern, RP Schleimer, A Kato
    Mucosal Immunol, 2019-10-22;13(1):86-95.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  10. 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential
    Authors: IJ Yeh, SC Chen, MC Yen, YH Wu, CH Hung, PL Kuo
    Nutrients, 2019-09-28;11(10):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels
    Authors: FL Collins, MD Stone, J Turton, LR McCabe, ECY Wang, AS Williams
    BMC Musculoskelet Disord, 2019-07-12;20(1):326.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro
    Authors: H Löfvall, A Katri, A D?browska, MA Karsdal, Y Luo, Y He, T Manon-Jens, MH Dziegiel, AC Bay-Jensen, CS Thudium, K Henriksen
    Sci Rep, 2019-02-28;9(1):3050.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Septins are critical regulators of osteoclastic bone resorption
    Authors: AMJ Møller, EM Füchtbauer, A Brüel, TL Andersen, XG Borggaard, NJ Pavlos, JS Thomsen, FS Pedersen, JM Delaisse, K Søe
    Sci Rep, 2018-08-29;8(1):13016.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis
    Authors: CF Kjelgaard-, A Platt, M Braddock, MA Jenkins, K Musa, E Graham, T Gantzel, G Slynn, ME Weinblatt, MA Karsdal, CS Thudium, AC Bay-Jensen
    Arthritis & rheumatology (Hoboken, N.J.), 2018-07-24;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  15. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain
    Authors: C Davenport, E Harper, KD Rochfort, H Forde, D Smith, PM Cummins
    J. Vasc. Res., 2018-04-10;55(2):111-123.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
    Authors: AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle
    MAbs, 2018-03-05;0(0):1-43.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance (SPR
  17. Cathepsin K Localizes to Equine Boneand Inhibits Bone Marrow Stem and Progenitor Cells Differentiation
    Authors: H Hussein, P Boyaka, J Dulin, D Russell, L Smanik, M Azab, AL Bertone
    J Stem Cells Regen Med, 2017-12-18;13(2):45-53.
    Species: Equine
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells
    Authors: A Sucur, Z Jajic, M Artukovic, MI Matijasevi, B Anic, D Flegar, A Markotic, T Kelava, S Ivcevic, N Kovacic, V Katavic, D Grcevic
    Arthritis Res. Ther., 2017-06-15;19(1):142.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis
    Authors: B Lu, Y Jiao, Y Wang, J Dong, M Wei, B Cui, Y Sun, L Wang, B Zhang, Z Chen, Y Zhao
    Exp. Mol. Med., 2017-05-19;49(5):e336.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity
    Authors: G Chinetti-G, M Daoudi, M Rosa, M Vinod, L Louvet, C Copin, M Fanchon, J Vanhoutte, B Derudas, L Belloy, S Haulon, C Zawadzki, S Susen, ZA Massy, J Eeckhoute, B Staels
    Circ. Res., 2017-04-24;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan
    Authors: A Kamalakar, CL Washam, NS Akel, BJ Allen, DK Williams, FL Swain, K Leitzel, A Lipton, D Gaddy, LJ Suva
    J. Bone Miner. Res., 2017-04-19;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity
    Authors: Giulia Bellini
    Pharmacol. Res, 2016-12-02;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  23. A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis
    Authors: Justin R Savage
    PLoS ONE, 2016-06-16;11(6):e0157310.
    Applications: Bioassay
  24. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro.
    Authors: Kasonga A, Deepak V, Kruger M, Coetzee M
    PLoS ONE, 2015-04-13;10(4):e0125145.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  25. Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy.
    Authors: Zhu K, Yi J, Xiao Y, Lai Y, Song P, Zheng W, Jiao H, Fan J, Wu C, Chen D, Zhou J, Xiao G
    J Biol Chem, 2015-02-03;290(13):8081-94.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  26. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-kappaB pathway in osteoclasts.
    Authors: Kalbasi Anaraki P, Patecki M, Tkachuk S, Kiyan Y, Haller H, Dumler I
    J Bone Miner Res, 2015-02-01;30(2):379-88.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis.
    Authors: Alshbool F, Mohan S
    PLoS ONE, 2014-12-05;9(12):e114357.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  28. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
    Authors: Zheng Y, Chow S, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland R, Dunstan C, Zhou H, Seibel M
    J Bone Miner Res, 2014-09-01;29(9):1938-49.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  29. Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCgamma-independent Ca2+ oscillation.
    Authors: Yeon J, Kim K, Choi S, Moon S, Park Y, Ryu B, Oh J, Kim M, Erkhembaatar M, Son Y, Kim S
    PLoS ONE, 2014-02-21;9(2):e88974.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  30. MiR-503 regulates osteoclastogenesis via targeting RANK.
    Authors: Chen C, Cheng P, Xie H, Zhou H, Wu X, Liao E, Luo X
    J Bone Miner Res, 2014-02-01;29(2):338-47.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
    Authors: Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak L, Yi Q, Yang J
    PLoS ONE, 2013-12-10;8(12):e82453.
    Species: Human
    Sample Types:
    Applications: Bioassay
  32. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.
    Authors: He W, Mazumder A, Wilder T, Cronstein B
    FASEB J, 2013-05-16;27(9):3446-54.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012-07-26;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  34. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle.
    Authors: Soe K, Delaisse JM
    J. Bone Miner. Res., 2010-10-01;25(10):2184-92.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  35. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Authors: Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM
    Leuk. Res., 2008-04-18;32(11):1661-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  36. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
    Authors: Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L, Cirulli N, Mancini L, Corrado A, Grassi FR, Grano M
    J. Pathol., 2007-05-01;212(1):47-55.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  37. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.
    Authors: Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL, Fu WM
    J. Biol. Chem., 2006-11-10;282(4):2346-54.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  38. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease.
    Authors: Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CW, Izumi Y, Taubman MA
    Am. J. Pathol., 2006-09-01;169(3):987-98.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  39. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
    Authors: Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
    Am. J. Pathol., 2003-11-01;163(5):2021-31.
    Applications: ELISA (Standard)

FAQs

  1. This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?

    • The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.

  2. Is this protein provided in trimeric form or monomer form? 

    • We do not define this protein as being exclusively a monomer, but we know that the protein is not fully associated into trimers because we need to use a cross-linking antibody for our in-house activity testing to cause multiple subunits of this protein to associate. This product has been shown to be biologically active in such testing when a cross-linking antibody is used. Therefore, we would expect for this protein to perform its expected biological function.

  3. What are the differences between the Recombinant Human TRANCE/RANK L/TNFSF11 Protein (Catalog # 390-TN) and the Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC)?

    • 6449-TEC is the truncated version of 390-TN, and it contains a 10-His tag in the N-terminus. The bioactivity of 390-TN and 6449-TEC are measured in the same assay described in the datasheet, "Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells." However, 390-TN utilizes a cross-linking antibody, MAB050, as it requires receptor trimerization which results in higher bioactivity. The ED50 for 390-TN is 1.5-7.5 ng/mL in the presence of MAB050, while the ED50 for 6449-TEC is 2-12 ng/mL.

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 Protein

Average Rating: 4.8 (Based on 8 Reviews)

5 Star
75%
4 Star
25%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human TRANCE/RANK L/TNFSF11 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Zijun Zhang on 05/17/2022
Application: In vitro bioactivity in cell culture
In vitro bioactivity in cell culture Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Anonymous on 12/31/2021
Application: In vitro bioactivity in cell culture
Reason for Rating: Steady quality! 60 ng/ml RANKL can induce monocyte to osteoclast very well.
In vitro bioactivity in cell culture Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Anonymous on 03/20/2021
Application: In vitro bioactivity in cell culture
Reason for Rating: 50ng/ml RANKL is good for induce the human monocyte to osteoclast.
In vitro bioactivity in cell culture Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Anonymous on 01/18/2021
Application: In vitro bioactivity in cell culture
Reason for Rating: 50ng/ml RANKL, 25ng/ml M-CSF in a-MEM works well for human osteoclasts.
In vitro bioactivity in cell culture Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Vaishali Sarode on 02/06/2019
Application: CellProlif
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Anonymous on 01/05/2018
Application: Characterization by MS
Other Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By Abby Sukarto on 05/16/2017
Recombinant Human TRANCE/RANK L/TNFSF11 Protein
By preety panwar on 05/18/2016
Application: CellProlif
Cell Proliferation Recombinant Human TRANCE/RANK L/TNFSF11 Protein 390-TN